Pre-Clinical News | Medical XPRT

Showcase

BOC Sciences Becomes the Largest PseudoUridine Supplier in the World

BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world. Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has ...

Sep. 16, 2021

By BOC Sciences

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...

Sep. 9, 2021

By Boehringer Ingelheim Vetmedica, Inc.

Exosome Targeting Services at Creative Biolabs Ready to Boost Drug Delivery Research

Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...

Sep. 1, 2021

By Creative Biolabs

Recruitment of the smallest infants in the Connection study paused

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

Aug. 25, 2021

By Infant Bacterial Therapeutics AB

Indee Labs Awarded Grant from the National Institute of Allergy & Infectious Disease

Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. ...

Aug. 24, 2021

By Indee Labs

Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers

Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. ...

Aug. 23, 2021

By Creative Proteomics

Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China

As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...

Aug. 23, 2021

By Lonza Group Ltd

Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China

As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...

Aug. 23, 2021

By Lonza Group Ltd

MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics ...

Aug. 19, 2021

By CD Genomics

CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC

CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully supports customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, ...

Aug. 19, 2021

By CD Genomics

Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company ...

Aug. 18, 2021

By Creative Proteomics

Creative Proteomics Accelerates Life Science Research Through Mass Spectrometry Platform

Creative Proteomics, experienced proteomics, metabolomics, and bioinformatics services supplier, has been well equipped with advanced technologies to meet the increasing needs of researchers and scientists in their proteomics and metabolomics related researches. In the past few years, the technology of mass spectrometry has been greatly developed and their applications broadened. Based on more ...

Aug. 17, 2021

By Creative Proteomics

Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available

Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital ...

Aug. 13, 2021

By Avery Biomedical Devices, Inc.

Avery Biomedical Letter to Medscape Regarding Diaphragm Pacing

Please find below a letter that our attorney sent to the editors of Medscape (parent company WebMD) who have published false information about our product. Medscape Letter Regarding Avery System Avery Biomedical Devices has an outstanding track record spanning over 45 years including an outstanding safety record, long term viability with some patients pacing for more than 35 years, and ...

Aug. 13, 2021

By Avery Biomedical Devices, Inc.

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy

Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, ...

Aug. 12, 2021

By Lonza Group Ltd

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Thursday, August 19 at 8:00 am ET. Vered Caplan, CEO of Orgenesis, will be hosting the presentation and answering questions from investors. To access the live presentation, please use the ...

Aug. 12, 2021

By Orgenesis

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...

Aug. 12, 2021

By Biocardia, Inc.

Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an ...

Aug. 10, 2021

By Second Genome Therapeutics

Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...

Aug. 5, 2021

By Second Genome Therapeutics

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin ...

Jul. 20, 2021

By Neuropathix, Inc.